Search clinical trials for: Anticorps bloquant PD-1

Total 769 results

Xiangya Hospital of Central South University
Wu Jieping Medical Foundation

Recruiting

Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomatic Brain Metastases

Non-small Cell Lung Cancer Metastatic | Brain Metastases

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

A Perspective, Self-control Study on the Progression of Carotid Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up

Carotid Artery Plaque | Plaque, Atherosclerotic | Immune Checkpoint Inhibitors | Programmed Cell Death Protein 1 Inhibitor | Intimal Medial Thickness of Internal Carotid Artery

China
The First Hospital of Jilin University

Not yet recruiting

CT and MRI in Prediction of Response in Patients With Gastric Cancer Following Neoadjuvant Chemotherapy and/or Immunotherapy

Gastric Cancer | Magnetic Resonance Imaging | Neoadjuvant Chemotherapy | Neoadjuvant Immunotherapy | Tomography, X-Ray Computed
Ruijin Hospital

Not yet recruiting

PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT

Lymphoma, Large B-Cell, Diffuse | Chemotherapy | Transplantation

China
Fujian Cancer Hospital

Not yet recruiting

Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy

NSCLC Stage IV

China
Shanghai Zhongshan Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in Locally Advanced Proximal Stomach Adenocarcinoma (Neo-PLANET)

Gastric Adenocarcinoma

China
Johnson & Johnson Healthcare Products Division...

Completed

Safety Study for an All-in-One Body and Personal Lubricant

Lubricating Agents

United States
Ningbo Cancer Hospital

Unknown

PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies

Advanced Cancer | Solid Tumor, Adult

China
MultiVir, Inc.

Unknown

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Lymphoma | Solid Tumor

United States
Sun Yat-sen University
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

PD-1 Blockade Combined With De-intensification Radical Chemoradiotherapy in Nasopharyngeal Carcinoma (DIAMOND)

Nasopharyngeal Carcinoma

China
Second Affiliated Hospital of Soochow University

Not yet recruiting

Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)

Carcinoma, Non-Small-Cell Lung | Carcinoma Breast

China
Chinese PLA General Hospital

Unknown

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer

Pancreatic Cancer

China
Huabo Biopharm Co., Ltd.

Recruiting

A Study of HB0025 Injection in Patients With Advanced Renal Cancer

Renal Cancer

China
Icahn School of Medicine at Mount Sinai

Recruiting

Pembrolizumab for Advanced NSCLC and PS 2-3

Non-Small Cell Lung Cancer (NSCLC)

United States
Cancer Institute and Hospital, Chinese Academy...
Peking University Cancer Hospital & Institute; Affiliated Cancer Hospital &... and other collaborators

Recruiting

Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL

Early-stage | Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type

China
Ruijin Hospital

Recruiting

Local Radiotherapy in Combination With Immunotherapy in Advanced Solid Tumors Patients

Solid Tumor

China
Ruijin Hospital

Recruiting

PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT

Lymphoma, Large B-Cell, Diffuse | Chemotherapy | Transplantation

China
Xiangya Hospital of Central South University

Active, not recruiting

Efficacy and Safety Study of Cardunilizumab in Soft Tissue Sarcoma

Sarcoma, Soft Tissue

China
Shanghai Changzheng Hospital

Unknown

Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer

Colorectal Cancer | Immunotherapy

China
Shanghai Zhongshan Hospital

Unknown

Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant

Liver Transplantation | Hepatocellular Carcinoma

China
LigaChem Biosciences, Inc.
AntibodyChem Biosciences, Inc.

Recruiting

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Advanced Solid Tumors

United States, Canada
First Affiliated Hospital of Guangxi Medical University

Recruiting

Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer

Cervical Cancer

China
Shanghai Zhongshan Hospital
Zhejiang Cancer Hospital; Sun Yat-sen University; Cancer Institute and Hospital... and other collaborators

Recruiting

Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC (iCROSS)

Esophageal Squamous Cell Carcinoma Stage II | Esophageal Squamous Cell Carcinoma Stage III

China
Sun Yat-sen University

Recruiting

Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma

Neoadjuvant Therapy | Apatinib | Carilizumab | Recurrent High-Grade Glioma

China
LaNova Medicines Limited

Terminated

Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

Advanced Solid Tumor

United States
Taizhou Hanzhong biomedical co. LTD

Active, not recruiting

Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors

Advanced Solid Tumor

China
Second Affiliated Hospital of Soochow University

Recruiting

A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

Advanced Solid Tumor | Refractory Tumor

China
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Immunotherapy in Upper Tract Urothelial Carcinoma (VESUVIO)

Urothelial Carcinoma
Shanghai Chest Hospital

Not yet recruiting

Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE) (RICE)

Chemotherapy | Immunotherapy | Concurrent Chemoradiotherapy | Esophageal Squamous Cell Carcinomas
Sun Yat-sen University

Recruiting

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Henan Cancer Hospital
Cttq

Unknown

Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody

Advanced Solid Tumor

China
Chinese PLA General Hospital

Unknown

A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC

Biliary Tract Cancer (BTC)

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study

Advanced Hepatocellular Carcinoma

China
Pfizer

Terminated

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

Melanoma | Soft Tissue Sarcoma | Mycosis Fungoides | Breast Carcinoma | Solid Tumors | Squamous Cell Carcinoma | Human Papillomavirus-Related Malignant Neoplasm | Merkel-cell Carcinoma

United States
Zhongshan Hospital Xiamen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study

Stage IV Gastric Cancer With Metastasis
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma

United States
University Hospital, Basel, Switzerland
GMP network of Basel

Completed

Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma (BaseTIL)

Advanced Melanoma

Switzerland
RenJi Hospital

Not yet recruiting

Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy (sPLENTY-pc)

Pediatric Cancer | Liver Cancer | Hepatoblastoma | Pediatric Solid Tumor | Transitional Cell Tumor

China
Peking University Cancer Hospital & Institute

Not yet recruiting

Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma

Collecting Duct Carcinoma

China
Sun Yat-sen University

Recruiting

Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer

Gastric or Gastroesophageal Junction Adenocarcinoma

China
Shanghai Zhongshan Hospital

Active, not recruiting

Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

Biliary Tract Cancer | PD-1 Antibody | Lenvatinib | Gemox

China
Chen Xiaoping

Recruiting

Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation

Hepatocellular Carcinoma

China
LI XIN-XIANG

Not yet recruiting

A Combination Therapy Including Anti-PD-1 Immunotherapy in Rectal Cancer With Refractory Distal Metastasis (Miracle-2)

Advanced Rectal Cancer | Distal Metastasis

China
Lei Li

Recruiting

PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer

Recurrent Cervical Carcinoma | Radiotherapy | Immune Checkpoint Inhibitors | Overall Survival | Anti-programmed Death-1 Antibody | Metastatic Cervical Carcinoma | Persistent Advanced Cervical Carcinoma | Objective Remission Rate | Progression-free Survival | Severe Adverse Events

China
Sichuan Cancer Hospital and Research Institute

Active, not recruiting

PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial

Nasopharyngeal Carcinoma | Chemoradiotherapy | PD-1 Inhibitors

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Unknown

Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
The Affiliated Hospital of Qingdao University

Unknown

PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC

NSCLC Stage IV | PD-1 | ARID1A

China
Third Military Medical University

Unknown

CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma

Burkitt Lymphoma | Acute Lymphoblastic Leukemia
Emory University
National Cancer Institute (NCI)

Withdrawn

Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases

Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Breast Carcinoma | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
Energenx Medical LTD.

Recruiting

Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer

NSCLC

China

Search clinical trials for: Anticorps bloquant PD-1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations